RxDoctor Payments DataLook up a doctor →

Mark Jalkut, MD

Urology · Raleigh, NCNPI 1326054859

Payments from drug & device makers

$516,059in general payments, 2019–2025

Across 672 payments — averaging $767.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$229K
  • AbbVie$88K
  • Sumitomo Pharma America, Inc.$78K
  • Janssen Research & Development, LLC$67K
  • Astellas Pharma US Inc$14K
  • Bayer$14K
  • plus $27K from 41 others
$30,589in research payments, 2019–2025

Across 11 payments — averaging $2780.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coloplast$30K
  • AbbVie$705

What the payments were for

  • Consulting fees$1,9953%
  • Speaking & faculty fees$39,68867%
  • Travel & lodging$2,1134%
  • Food & beverage$11,18819%
  • Education$4,5298%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$516,059 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$444,777
Medicare patients
732
Services billed
14,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide84$1,206,498
XtandiEnzalutamide88$1,130,174
NubeqaDarolutamide62$763,591
OrgovyxRelugolix89$275,923
ZytigaAbiraterone Acetate12$125,876
MyrbetriqMirabegron84$92,982
GemtesaVibegron69$64,155
Testosterone49$11,234
Tamsulosin Hcl665$11,195
Abiraterone Acetate15$9,315
Potassium Citrate ErPotassium Citrate85$7,962
Solifenacin Succinate91$4,706
Testosterone Cypionate57$3,587
Silodosin52$3,419
Finasteride126$1,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Zytiga$689$1,332,37496 claims
Astellas Pharma US IncXtandi, Myrbetriq$13,612$1,223,156172 claims
BayerNubeqa$13,538$763,59162 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$78,091$340,078158 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$37$9,31515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.

Other urology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →